Amneal Pharmaceuticals (AMRX) Cost of Revenue (2017 - 2026)

Amneal Pharmaceuticals' Cost of Revenue history runs 10 years deep, the most recent figure standing at $402.4 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 8.45% year-over-year to $402.4 million in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 4.26% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 7.44% from the prior year.
• Cost of Revenue fell to $402.4 million in Q1 2026 per AMRX's latest filing, from $517.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $517.1 million in Q4 2025 and bottomed at $764000.0 in Q1 2022.
• The 5-year median for Cost of Revenue is $421.1 million (2024), against an average of $356.0 million.
• Across the five-year window, Cost of Revenue sank 78.67% in 2022 and surged 49553.66% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $394.4 million in 2022, then advanced by 8.31% to $427.2 million in 2023, then rose by 9.48% to $467.6 million in 2024, then rose by 10.58% to $517.1 million in 2025, then fell by 22.18% to $402.4 million in 2026.
• Per Business Quant, the three latest AMRX Cost of Revenue figures stand at $402.4 million (Q1 2026), $517.1 million (Q4 2025), and $510.5 million (Q3 2025).